Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today the launch of the CONSTRUX ® Mini PEEK Titanium Composite ™ (PTC) Spacer System through its spine distribution network. This anterior cervical interbody system incorporates a unique technology that combines the benefits of PEEK’s imaging capabilities with the potential of bone ingrowth from porous titanium endplates. Dr. Scott Stanley, Medical Director of the Spine Program at Parker Adventist Hospital in Parker, Colorado, who is the primary surgeon innovator behind the technology stated, "After years of hard work in this product's development, I am thrilled to utilize this implant for my patients. I believe that the porous interface will allow for potential bone ingrowth as demonstrated in the orthopedic joint arthroplasty literature. This product will allow patients to return to extracurricular activities and activities of daily living in a timely fashion." The CONSTRUX ® Mini PEEK Titanium Composite ™ (PTC) Spacer System has porous titanium endplates that provide a 3D porous material with the potential for bone ingrowth that may create a bond between the bone and the implant. The implant also features a PEEK core, which allows for post and intraoperative imaging without the severe image distortion associated with metal designs currently on the market. “We are very excited about the launch of this novel, differentiated cervical interbody system. It represents the beginning of a series of product launches in 2013 that will bring our cervical implant product offering to the forefront of the industry,” said President and Chief Executive Officer Robert Vaters. This PEEK/ Titanium hybrid offers three footprints and various heights to address the cervical interbody fusion solution. These implants work with the CONSTRUX Mini PEEK Spacer System instrument trays currently in the field. About Orthofix: Orthofix International N.V. is a diversified, global medical device company focused on developing and delivering innovative repair and regenerative solutions to the spine and orthopedic markets. Orthofix’s products are widely distributed around the world to surgeons and patients via Orthofix’s sales representatives and its subsidiaries, and via collaborations with other leading orthopedic product companies. In addition, Orthofix is collaborating on R&D activities with leading research and clinical organizations such as the Musculoskeletal Transplant Foundation, the Orthopedic Research and Education Foundation, and Texas Scottish Rite Hospital for Children. For more information about Orthofix, please visit www.orthofix.com.